ResearcherTampere UniversityActive in the last 2 years
Reea Ahola
Matched on ORCID iD 0000-0002-9702-2729; OpenAlex author ID A5089557077. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 7
- Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
- Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
- Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2022.05.001↗
- In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma… First author DOI 10.1177/1457496920911807↗
- Access to radical resections of pancreatic cancer is region-dependent despite the public healthcare system in Finland. Co-author DOI 10.1136/jech-2017-210187↗
- Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs.10560↗
- Patients with resected, histologically re-confirmed pancreatic ductal adenocarcinoma (PDAC) can achieve long-term survival despite T3 tumour or nodal involveme… Co-author DOI 10.1016/j.pan.2017.07.192↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Johanna Laukkarinen · 7 shared papers, 2017–2026 · strength 0.97
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Paper Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. DOI 10.1016/j.pan.2022.05.001↗
- Benediktas Kurlinkus · 4 shared papers, 2020–2026 · strength 0.72
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Paper Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. DOI 10.1016/j.pan.2022.05.001↗
- Asif Halimi · 4 shared papers, 2020–2026 · strength 0.72
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Paper Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. DOI 10.1016/j.pan.2022.05.001↗
- Eline S. Zwart · 4 shared papers, 2020–2026 · strength 0.72
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Paper Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. DOI 10.1016/j.pan.2022.05.001↗
- Guralp Onur Ceyhan · 4 shared papers, 2020–2026 · strength 0.72
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Paper Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. DOI 10.1016/j.pan.2022.05.001↗
- Giulio Belfiori · 2 shared papers, 2024–2026 · strength 0.42
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Patrick Maisonneuve · 2 shared papers, 2024–2026 · strength 0.42
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Keith John Roberts · 2 shared papers, 2024–2026 · strength 0.42
- Paper Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analy… DOI 10.1007/s00423-026-04291-0↗
- Paper Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective anal… DOI 10.1093/bjsopen/zrae076↗
- Giuseppe Malleo · 1 shared paper, 2026 · strength 0.22
- Marco Del Chiaro · 1 shared paper, 2026 · strength 0.22
- Francesco Giovinazzo · 1 shared paper, 2026 · strength 0.22
- Laura Maggino · 1 shared paper, 2026 · strength 0.22
- Ernesto Sparrelid · 1 shared paper, 2026 · strength 0.22
- Elena B. Rangelova · 1 shared paper, 2026 · strength 0.22
- Gabriella Lionetto · 1 shared paper, 2026 · strength 0.22
- Massimo Falconi · 1 shared paper, 2026 · strength 0.22
- Geert Kazemier M · 1 shared paper, 2026 · strength 0.22
- Stefano Crippa · 1 shared paper, 2026 · strength 0.22
- Roberto Salvia · 1 shared paper, 2026 · strength 0.22
- Rupaly Pandé · 1 shared paper, 2024 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.